Blog
RSS FeedPosted by Michael Wonder on 02 Sep 2020
Talazoparib in breast cancer: hint of considerable added benefit
1 September 2020 - Advantages in health related quality of life, symptoms and side effects outweigh disadvantages. ...
Posted by Michael Wonder on 27 Aug 2020
Mylan, Lupin launch etanercept biosimilar in Germany
26 August 2020 - The launch marks the first European market entry for Nepexto. ...
Posted by Michael Wonder on 17 Aug 2020
Castration-resistant prostate cancer with a high risk of metastasis: enzalutamide has an additional benefit
17 August 2020 - New data from the PROSPER study shows benefit in overall survival. ...
Posted by Michael Wonder on 13 Aug 2020
Predictors of negotiated prices for new drugs in Germany
13 August 2020 - In Germany, all new, innovative medicines are subject to an early benefit assessment by the German Federal ...
Posted by Michael Wonder on 06 Aug 2020
Darolutamide in prostate cancer: indication of considerable added benefit
3 August 2020 - Advantages in overall survival, symptoms and health-related quality of life. ...
Posted by Michael Wonder on 17 Jul 2020
Determination of the target population in early benefit assessments in Germany: challenges for non-small-cell lung cancer
17 July 2020 - Dossiers submitted for early benefit assessments in Germany also provide information on the precise determination of the ...
Posted by Michael Wonder on 11 Jul 2020
How can cancer drug prices better match their benefits? Germany offers a cost-saving model
10 July 2020 - After Germany revamped its approach to purchasing medicines a decade ago, the prices negotiated by the ...
Posted by Michael Wonder on 07 Jul 2020
Lessons from the impact of price regulation on the pricing of anti-cancer drugs in Germany
7 July 2020 - Worldwide spending on prescription drugs has increased dramatically in recent years. Although this increase has been particularly ...
Posted by Michael Wonder on 07 Jul 2020
Network meta-analyses: no compensation for weak evidence
7 July 2020 - BMJ publication headed by IQWiG: relevant controlled studies and individual patient data are necessary for informative ...
Posted by Michael Wonder on 05 Jul 2020
Ceftolozane/tazobactam: new treatment option for severe infections, but no proof of superiority
1 July 2020 - Informative comparative data are missing / resistance situation not sufficiently considered in approval studies. ...
Posted by Michael Wonder on 25 Jun 2020
The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany
15 June 2020 - Payers are increasingly calling for the value of new drugs to be measured explicitly. ...
Posted by Michael Wonder on 24 Jun 2020
Germany first in EU to get Novartis’ SMA gene therapy, costing almost 2 million euros
24 June 2020 - Novartis is set to launch its one-off gene therapy Zolgensma for the ultra-rare muscle-wasting disease spinal ...
Posted by Michael Wonder on 15 Jun 2020
Romosozumab in osteoporosis: considerable added benefit for women after menopause
15 June 2020 - Fewer vertebral fractures and fewer other typical fractures in postmenopausal women with severe osteoporosis at high ...
Posted by Michael Wonder on 03 Jun 2020
Lower prices and greater patient access — lessons from Germany’s drug purchasing structure
3 June 2020 - The German system for determining drug prices features collective negotiations on the part of competing health plans. ...
Posted by Michael Wonder on 02 Jun 2020
Ribociclib succinate in breast cancer: added benefit for certain post-menopausal women
2 June 2020 - Re-valuations after the expiry of the time limit new data cuts confirm advantages and disadvantages ...